These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 29698567)

  • 1. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
    Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
    Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p.
    Zhang B; Li H; Li D; Sun H; Li M; Hu H
    Gene; 2019 Jun; 700():139-148. PubMed ID: 30898698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
    Xie L; Wang PX; Zhang P; Zhang XJ; Zhao GN; Wang A; Guo J; Zhu X; Zhang Q; Li H
    J Hepatol; 2016 Jul; 65(1):113-124. PubMed ID: 27016281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
    Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
    J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
    Gao L; Wang PX; Zhang Y; Yu CJ; Ji Y; Wang X; Zhang P; Jiang X; Jin H; Huang Z; Zhang ZR; Li H
    J Hepatol; 2016 Jul; 65(1):125-136. PubMed ID: 27032381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice.
    Yu CJ; Wang QS; Wu MM; Song BL; Liang C; Lou J; Tang LL; Yu XD; Niu N; Yang X; Zhang BL; Qu Y; Liu Y; Dong ZC; Zhang ZR
    Hepatology; 2018 Nov; 68(5):1769-1785. PubMed ID: 29704259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis.
    Xiao XH; Wang YD; Qi XY; Wang YY; Li JY; Li H; Zhang PY; Liao HL; Li MH; Liao ZZ; Yang J; Xu CX; Wen GB; Liu JH
    Int J Obes (Lond); 2018 Aug; 42(8):1418-1430. PubMed ID: 30006580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity.
    An S; Zhao LP; Shen LJ; Wang S; Zhang K; Qi Y; Zheng J; Zhang XJ; Zhu XY; Bao R; Yang L; Lu YX; She ZG; Tang YD
    Hepatology; 2017 Dec; 66(6):1866-1884. PubMed ID: 28718215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
    Xiang M; Wang PX; Wang AB; Zhang XJ; Zhang Y; Zhang P; Mei FH; Chen MH; Li H
    J Hepatol; 2016 Jun; 64(6):1365-77. PubMed ID: 26860405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1.
    Wu L; Liu Y; Zhao Y; Li M; Guo L
    Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1.
    Tang M; Cao H; Ma Y; Yao S; Wei X; Tan Y; Liu F; Peng Y; Fan N
    J Transl Med; 2024 Jul; 22(1):671. PubMed ID: 39033101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice.
    Li Y; Sun JP; Wang J; Lu WH; Xie LY; Lv J; Li HX; Yang SF
    Biochem Biophys Res Commun; 2019 Aug; 516(3):858-865. PubMed ID: 31266632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
    Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
    Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressing NLRP2 expression accelerates hepatic steatosis: A mechanism involving inflammation and oxidative stress.
    Li C; Liu Q; Xie L
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):22-29. PubMed ID: 30454891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor.
    Ka SO; Bang IH; Bae EJ; Park BH
    FASEB J; 2017 Sep; 31(9):3999-4010. PubMed ID: 28536120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway.
    Lu Y; Jiang Z; Dai H; Miao R; Shu J; Gu H; Liu X; Huang Z; Yang G; Chen AF; Yuan H; Li Y; Cai J
    Hepatology; 2018 Apr; 67(4):1303-1319. PubMed ID: 29091299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.